KURE
KraneShares MSCI All China Health Care Index ETF
Set alert
17.62 USD -0.18 -1.01%
17.50 Day range 17.69
14.52 52-week range 19.72
- YTD
- +3.40%
- 1 year
- -6.92%
- Open
- 17.62
- Prev close
- 17.80
- Mkt cap
- 109.44M
- Vol
- 21.42K
- Avg vol
- 75.63K
- EPS
- 0.793678
- P/E
- 22.20
- Div yield
- 0.00%
More statistics
- Low
- 17.50
- High
- 17.69
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 15.32
- 200-d avg
- 14.58
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 20.40
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 15.32
- 200-day average
- 14.58
About KraneShares MSCI All China Health Care Index ETF
The fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in instruments in its underlying index or in instruments that have economic characteristics similar to those in the underlying index. The underlying index is a free float adjusted market capitalization weighted index, subject to the 10/40 Constraint, which is designed to measure the equity market performance of Chinese companies in the healthcare sector. The fund is non-diversified.
News
- Trump Unveils 'Great Healthcare Plan,' Takes Aim At PBM 'Kickbacks'
- Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily'
- Should EM Investors Trim or Retain Their China Exposure?
- Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms
- Capitalize on China Healthcare Fundraising With KURE
- Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing
- Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More'
- Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'
- Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
- Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'
Your note
Sign in to keep a note on KURE — it syncs with the Stock Master app.